Revista espanola de medicina nuclear e imagen molecular最新文献

英文中文

Atypical presentation of angiosarcoma detected by ¹⁸F-FDG PET/CT as a solitary mediastinal lesion. 18F-FDG PET/CT检测血管肉瘤为孤立纵隔病变的不典型表现。

Revista espanola de medicina nuclear e imagen molecular

Pub Date : 2026-01-02 DOI: 10.1016/j.remnie.2025.500275

N Hou, H Dai, R Huang, M Su

引用次数: 0

Relationship between metabolic parameters and asphericity derived from ¹⁸F-FDG PET/CT and stage in small cell lung cancer. 小细胞肺癌代谢参数、18F-FDG PET/CT非球形度与分期的关系

Revista espanola de medicina nuclear e imagen molecular

Pub Date : 2026-01-02 DOI: 10.1016/j.remnie.2025.500276

K Şeker, Ö Ulaş, Z Hasbek

Purpose: This study retrospectively evaluated the relationship between disease stage and metabolic parameters, along with asphericity, derived from ¹⁸F-FDG PET/CT images in patients with Small Cell Lung Cancer (SCLC).

Methods: We analyzed primary tumor metabolic parameters, including maximum and mean standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), as well as Asphericity (ASP). Disease staging was determined from ¹⁸F-FDG PET/CT images as either limited-stage (LS) or extensive-stage (ES). Statistical analyses assessed the correlation among these metabolic parameters and ASP, their relationship with disease stage, their ability to predict disease stage.

Results: The study included 134 SCLC patients (mean age: 62.3; 112 males, 22 females). Of these, 61.2% had ES and 38.8% had LS disease. MTV, TLG, and ASP values were significantly higher in the ES group than in the LS group (p < 0.001). In the multivariate binary logistic regression analysis, Age (p = 0.025), Gender (p = 0.033), and ASP (p = 0.001) were identified as independent predictors of disease stage. Notably, a one-unit increase in ASP was associated with a 6.35-fold increase in the likelihood of Extensive-Stage disease (OR = 6.350). In ROC analysis, MTV, TLG, and ASP significantly distinguished disease stages (p < 0.001) with optimal cut-off values of 45.05, 382.81, and 0.536, respectively.

Conclusion: Relying solely on SUVmax for SCLC patient evaluation may be insufficient. Incorporating other metabolic parameters like MTV and TLG, in addition to ASP, which was identified as a strong independent predictor, may enhance the understanding of tumor behavior during staging. These additional parameters can significantly aid in comprehensive patient assessment.

目的：本研究回顾性评估小细胞肺癌（SCLC）患者18F-FDG PET/CT图像中代谢参数与疾病分期之间的关系。方法：我们分析原发性肿瘤代谢参数，包括最大和平均标准化摄取值（SUVmax, SUVmean），代谢肿瘤体积（MTV），总病变糖酵解（TLG），以及非球形度（ASP）。根据18F-FDG PET/CT图像确定疾病分期为有限期（LS）或广泛期（ES）。统计分析评估这些代谢参数与ASP之间的相关性、与疾病分期的关系以及预测疾病分期的能力。结果：研究纳入134例SCLC患者（平均年龄：62.3岁；男性112例，女性22例）。其中61.2%为ES， 38.8%为LS。ES组的MTV、TLG和ASP值明显高于LS组(p)。结论：单纯依靠SUVmax对SCLC患者的评价可能是不够的。结合其他代谢参数，如MTV和TLG，除了ASP，这被认为是一个强大的独立预测因子，可以增强对分期期间肿瘤行为的理解。这些额外的参数可以显著地帮助全面的病人评估。

{"title":"Relationship between metabolic parameters and asphericity derived from <sup>18</sup>F-FDG PET/CT and stage in small cell lung cancer.","authors":"K Şeker, Ö Ulaş, Z Hasbek","doi":"10.1016/j.remnie.2025.500276","DOIUrl":"10.1016/j.remnie.2025.500276","url":null,"abstract":"<p><strong>Purpose: </strong>This study retrospectively evaluated the relationship between disease stage and metabolic parameters, along with asphericity, derived from <sup>18</sup>F-FDG PET/CT images in patients with Small Cell Lung Cancer (SCLC).</p><p><strong>Methods: </strong>We analyzed primary tumor metabolic parameters, including maximum and mean standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), as well as Asphericity (ASP). Disease staging was determined from <sup>18</sup>F-FDG PET/CT images as either limited-stage (LS) or extensive-stage (ES). Statistical analyses assessed the correlation among these metabolic parameters and ASP, their relationship with disease stage, their ability to predict disease stage.</p><p><strong>Results: </strong>The study included 134 SCLC patients (mean age: 62.3; 112 males, 22 females). Of these, 61.2% had ES and 38.8% had LS disease. MTV, TLG, and ASP values were significantly higher in the ES group than in the LS group (p < 0.001). In the multivariate binary logistic regression analysis, Age (p = 0.025), Gender (p = 0.033), and ASP (p = 0.001) were identified as independent predictors of disease stage. Notably, a one-unit increase in ASP was associated with a 6.35-fold increase in the likelihood of Extensive-Stage disease (OR = 6.350). In ROC analysis, MTV, TLG, and ASP significantly distinguished disease stages (p < 0.001) with optimal cut-off values of 45.05, 382.81, and 0.536, respectively.</p><p><strong>Conclusion: </strong>Relying solely on SUVmax for SCLC patient evaluation may be insufficient. Incorporating other metabolic parameters like MTV and TLG, in addition to ASP, which was identified as a strong independent predictor, may enhance the understanding of tumor behavior during staging. These additional parameters can significantly aid in comprehensive patient assessment.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500276"},"PeriodicalIF":0.0,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145902138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pretreatment 18F-FDG PET/CT in predicting the survival of patients with hepatic neuroendocrine tumors 预处理18F-FDG PET/CT预测肝神经内分泌肿瘤患者的生存。

Revista espanola de medicina nuclear e imagen molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remnie.2025.500198

Y. Zhang , G. Liu , L. Zhong , B. Li , Y. Zhang

Objective

To investigate the prognostic value of pretreatment 2-[¹⁸F]-fluoro-2-deoxy-d-glucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with hepatic neuroendocrine tumors (HNET).

Methods

In total, 41 patients were included in this study. PET-derived metabolic parameters, including maximum and mean standardized uptake values (SUV_max and SUV_mean, respectively), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), of the tumors were measured. Meanwhile, clinical data, including tumor pathological findings such as the Ki-67 index were also assessed. Progression-free survival (PFS) and overall survival (OS) were evaluated. Univariate and multivariate analyses were performed to predict the prognostic value of clinical variables and PET-derived metabolic parameters in HNET patients. Correlation between PET-derived metabolic parameters and Ki-67 was estimated.

Results

Univariate analyses revealed that among PET-derived metabolic parameters, SUV_max, SUV_mean, and TLG were significant prognostic factors for OS (P < .05). Among clinical variables, the Ki-67 index and radical surgical resection were significant factors for both PFS and OS (P < .05). In multivariate analyses, only Ki-67 index was an independent prognostic factor for both PFS and OS (P < .05). Ki-67 index presented correlates with SUV_max and SUV_mean (R = 0.566, P < .001, R = 0.493, P = .001, respectively).

Conclusions

In patients with HNET, the Ki-67 index was an independent prognostic factor for both PFS and OS, while SUV_max, SUV_mean, and TLG measured on pretreatment ¹⁸F-FDG PET/CT scans were prognostic factors for predicting OS. Ki-67 index also presented correlates with SUV_max and SUV_mean. ¹⁸F-FDG-PET may be useful as quantitative predicting prognostic imaging biomarkers, especially in poorly differentiated HNET.

目的：探讨预处理2-[18F]-氟-2-脱氧-d-葡萄糖（18F- fdg）正电子发射断层扫描/计算机断层扫描（PET/CT）对肝神经内分泌肿瘤（HNET）患者的预后价值。方法：本研究共纳入41例患者。测量pet衍生的代谢参数，包括肿瘤的最大和平均标准化摄取值（分别为SUVmax和SUVmean）、代谢肿瘤体积（MTV）和病变总糖酵解（TLG）。同时对肿瘤病理表现Ki-67指数等临床资料进行评估。评估无进展生存期(PFS)和总生存期(OS)。通过单因素和多因素分析来预测临床变量和pet衍生代谢参数在HNET患者中的预后价值。估计pet衍生代谢参数与Ki-67之间的相关性。结果：单因素分析显示，在PET衍生的代谢参数中，SUVmax、SUVmean和TLG是OS的重要预后因素（P max和SUVmean (R = 0.566， P)）。结论：在HNET患者中，Ki-67指数是PFS和OS的独立预后因素，而预处理18F-FDG PET/CT扫描测量的SUVmax、SUVmean和TLG是预测OS的预后因素。Ki-67指数与SUVmax和SUVmean也存在相关性。18F-FDG-PET可作为定量预测预后的影像学生物标志物，特别是在低分化的HNET中。

{"title":"Pretreatment 18F-FDG PET/CT in predicting the survival of patients with hepatic neuroendocrine tumors","authors":"Y. Zhang , G. Liu , L. Zhong , B. Li , Y. Zhang","doi":"10.1016/j.remnie.2025.500198","DOIUrl":"10.1016/j.remnie.2025.500198","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the prognostic value of pretreatment 2-[<sup>18</sup>F]-fluoro-2-deoxy-<span>d</span>-glucose (<sup>18</sup><span>F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with hepatic neuroendocrine tumors (HNET).</span></div></div><div><h3>Methods</h3><div><span>In total, 41 patients were included in this study. PET-derived metabolic parameters, including maximum and mean standardized uptake values (SUV</span><sub>max</sub> and SUV<sub>mean</sub><span>, respectively), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), of the tumors were measured. Meanwhile, clinical data, including tumor pathological findings such as the Ki-67 index were also assessed. Progression-free survival (PFS) and overall survival (OS) were evaluated. Univariate and multivariate analyses were performed to predict the prognostic value of clinical variables and PET-derived metabolic parameters in HNET patients. Correlation between PET-derived metabolic parameters and Ki-67 was estimated.</span></div></div><div><h3>Results</h3><div><span>Univariate analyses revealed that among PET-derived metabolic parameters, SUV</span><sub>max</sub>, SUV<sub>mean</sub><span>, and TLG were significant prognostic factors for OS (</span><em>P</em> < .05). Among clinical variables, the Ki-67 index and radical surgical resection were significant factors for both PFS and OS (<em>P</em> < .05). In multivariate analyses, only Ki-67 index was an independent prognostic factor for both PFS and OS (<em>P</em> < .05). Ki-67 index presented correlates with SUV<sub>max</sub> and SUV<sub>mean</sub> (R = 0.566, <em>P</em> < .001, R = 0.493, <em>P</em> = .001, respectively).</div></div><div><h3>Conclusions</h3><div>In patients with HNET, the Ki-67 index was an independent prognostic factor for both PFS and OS, while SUV<sub>max</sub>, SUV<sub>mean</sub>, and TLG measured on pretreatment <sup>18</sup>F-FDG PET/CT scans were prognostic factors for predicting OS. Ki-67 index also presented correlates with SUV<sub>max</sub> and SUV<sub>mean</sub>. <sup>18</sup>F-FDG-PET may be useful as quantitative predicting prognostic imaging biomarkers, especially in poorly differentiated HNET.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 1","pages":"Article 500198"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Massive subcutaneous emphysema and complete resorption images detected on [18F]-FDG PET/CT [18F]-FDG PET/CT检测大量皮下肺气肿和完全吸收图像。

Revista espanola de medicina nuclear e imagen molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remnie.2025.500180

M.T. Tatoğlu , H. Uslu

Subcutaneous emphysema may occur iatrogenically, spontaneously, or post-traumatically as a result of free air passage under the skin from the respiratory tract or gastrointestinal tract. In this case, we present the typical appearance of a case of massive subcutaneous emphysema observed on [18F]-FDG PET/CT for metabolic characterization due to a massive lesion in the lung and the images of complete resorption after seven months.

皮下肺气肿的发生可能是医源性的，也可能是自发的，也可能是创伤后的，因为呼吸道或胃肠道的空气在皮肤下自由流通。在本病例中，我们报告了一例典型的大面积皮下肺气肿的表现，在[18F]-FDG PET/CT上观察到，由于肺部有大面积病变，7个月后完全吸收的图像。

引用次数: 0

Metabolic alterations on brain [18F]FDG PET in a case of postcoital transient global amnesia 1例性交后短暂性全身性遗忘的FDG - PET脑代谢改变[18F]。

Revista espanola de medicina nuclear e imagen molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remnie.2025.500203

F. Sebastián Palacid, B. Pérez López, N. Álvarez Mena, C. Riola Parada, C. Gamazo Laherrán, R. Ruano Pérez

引用次数: 0

Treatment with radionuclide-labeled peptides in refractory meningiomas: Updated review and clinical perspectives 放射性核素标记肽治疗难治性脑膜瘤：最新综述和临床前景。

Revista espanola de medicina nuclear e imagen molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remnie.2025.500218

E. Abou Jokh Casas , J.L. Vercher Conejero , A. Repetto , P. Bello Arques , T. Cambil Molina , A. Rodriguez Gasén , J.A. Vallejo Casas

The use of theragnostics in nuclear medicine has significantly advanced, particularly peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Meningiomas often overexpress somatostatin receptors (SSTR), making them potential candidates for PRRT. However, the lack of large-scale standardized trials limits its clinical application.

Meningiomas are the most common primary intracranial tumors; the treatment of choice for which is surgical resection or, if that's not possible, radiotherapy. However, some cases are refractory to standard treatments, leading to the exploration of other therapeutic options, such as targeted therapy with radioligands. Studies have demonstrated promising results with [¹⁷⁷Lu]Lu-DOTATATE in meningiomas expressing SSTR2, improving progression-free survival (PFS) in refractory cases.

Current evidence suggests that PRRT is a viable option for refractory meningiomas with high SSTR expression. However, further clinical trials are needed to establish standardized protocols, optimize patient selection criteria, and explore combination therapy strategies to improve outcomes. This review highlights the mechanisms, clinical applications, and future perspectives of [¹⁷⁷Lu]Lu-DOTATATE in meningiomas, providing insights into its expanding role in this pathology.

核医学诊疗学的应用有了显著的进步，特别是在神经内分泌肿瘤中的肽受体放射性核素治疗（PRRT）。脑膜瘤通常过度表达生长抑素受体（SSTR），使其成为PRRT的潜在候选者。然而，缺乏大规模的标准化试验限制了其临床应用。脑膜瘤是最常见的原发性颅内肿瘤；治疗的选择是手术切除，如果不可能的话，放射治疗。然而，一些病例对标准治疗难以治愈，导致探索其他治疗选择，如放射配体靶向治疗。研究表明，[177Lu]Lu-DOTATATE在表达SSTR2的脑膜瘤中具有良好的效果，可改善难治性病例的无进展生存期（PFS）。目前的证据表明，PRRT是高SSTR表达的难治性脑膜瘤的可行选择。然而，需要进一步的临床试验来建立标准化的方案，优化患者选择标准，并探索联合治疗策略以改善结果。本文综述了[177Lu]Lu-DOTATATE在脑膜瘤中的作用机制、临床应用和未来前景，为其在脑膜瘤病理中的作用提供了新的见解。

{"title":"Treatment with radionuclide-labeled peptides in refractory meningiomas: Updated review and clinical perspectives","authors":"E. Abou Jokh Casas , J.L. Vercher Conejero , A. Repetto , P. Bello Arques , T. Cambil Molina , A. Rodriguez Gasén , J.A. Vallejo Casas","doi":"10.1016/j.remnie.2025.500218","DOIUrl":"10.1016/j.remnie.2025.500218","url":null,"abstract":"<div><div>The use of theragnostics in nuclear medicine has significantly advanced, particularly peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Meningiomas often overexpress somatostatin receptors (SSTR), making them potential candidates for PRRT. However, the lack of large-scale standardized trials limits its clinical application.</div><div>Meningiomas are the most common primary intracranial tumors; the treatment of choice for which is surgical resection or, if that's not possible, radiotherapy. However, some cases are refractory to standard treatments, leading to the exploration of other therapeutic options, such as targeted therapy with radioligands. Studies have demonstrated promising results with [<sup>177</sup>Lu]Lu-DOTATATE in meningiomas expressing SSTR2, improving progression-free survival (PFS) in refractory cases.</div><div>Current evidence suggests that PRRT is a viable option for refractory meningiomas with high SSTR expression. However, further clinical trials are needed to establish standardized protocols, optimize patient selection criteria, and explore combination therapy strategies to improve outcomes. This review highlights the mechanisms, clinical applications, and future perspectives of [<sup>177</sup>Lu]Lu-DOTATATE in meningiomas, providing insights into its expanding role in this pathology.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 1","pages":"Article 500218"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond the standard: Enhancing prostate bed and regional lymph node detection in prostate cancer patients with early and delayed imaging in [68 Ga]Ga-PSMA-11 PET/CT 超越标准：通过[68 Ga]Ga- psma -11 PET/CT早期和延迟成像增强前列腺癌患者的前列腺床和区域淋巴结检测。

Revista espanola de medicina nuclear e imagen molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remnie.2025.500184

A. Aghaee , Z. Bakhshi , V. Roshanravan , N. Norouzbeigi , H. Dadgar , E. Askari , K. Aryana , S. Shafiei , S. Soltani , S. Sadeghpour

Objectives

This study aims to evaluate the diagnostic value of early static and delayed imaging in conjunction with standard 68Ga-PSMA-11 PET/CT scans to detect prostate malignant lesions in prostate cancer patients.

Methods

One hundred and thirty-eight prostate cancer patients underwent routine [68 Ga]Ga-PSMA-11 PET/CT imaging, 4-minute static acquisition post-injection, and delayed imaging 3 h post-injection. The imaging results were analysed for lesion count, type, localisation, and maximum standardised uptake values.

Results

57.97% exhibited positive findings for pathologic prostatic lesions in the standard PET scans (SUV_max: 10.24). In contrast, early PET imaging detected lesions in 58.01% of patients (SUV_max of 5.86), while delayed scans revealed lesions suggestive of malignancy in 55.45% of patients (SUV_max of 12.79). The analysis demonstrated a statistically significant difference in SUV_max values across the time points (P < .001). Pathologic lymph nodes on images 60 min p.i. were revealed by an SUV max 60 min p.i.: 15.78; this number for the first 4 min and after 3 h were 7.36, 19.19, respectively. Metastatic bone lesions on WB were found in 38 patients, more than the ESI (n = 37) and DI (n = 24). In comparison, urinary bladder activity assessment was detectable with the WB imaging SUV_max 60 min 11.07. Even though the SUV max for ESI and DI were 6.95 and 31.97, respectively. In the statistical analysis, pathologic radiotracer uptake in tumour lesions was statistically higher in ESI and WB than in urinary bladder activity.

Conclusions

The findings indicate that neither early [68 Ga]Ga-PSMA-11 PET/CT nor delayed imaging significantly enhanced the overall detection rate of malignant lesions in prostate cancer patients. However, the early 4-minute post-injection acquisition of PET images proved beneficial for distinguishing local bladder invasion more effectively.

目的：本研究旨在评价早期静态和延迟成像结合标准68Ga-PSMA-11 PET/CT扫描对前列腺癌患者前列腺恶性病变的诊断价值。方法：138例前列腺癌患者行常规[68 Ga]Ga- psma -11 PET/CT成像，注射后4分钟静态采集，注射后3小时延迟成像。影像学结果分析病变计数、类型、定位和最大标准化摄取值。结果：57.97%的患者在标准PET扫描中表现为前列腺病理性病变阳性（SUVmax: 10.24）。相比之下，58.01%的患者（SUVmax为5.86）在早期PET成像中发现病变，而55.45%的患者（SUVmax为12.79）在延迟扫描中发现提示恶性病变。分析表明，SUVmax值在不同时间点有统计学意义差异（p max 60 min 11.07）。尽管ESI和DI的SUV max分别为6.95和31.97。在统计分析中，病理放射性示踪剂在肿瘤病变中的摄取在ESI和WB中高于膀胱活动。结论：研究结果表明，早期[68 Ga]Ga- psma -11 PET/CT和延迟显像均未显著提高前列腺癌患者恶性病变的整体检出率。然而，注射后早期4分钟的PET图像采集有助于更有效地识别局部膀胱侵犯。

{"title":"Beyond the standard: Enhancing prostate bed and regional lymph node detection in prostate cancer patients with early and delayed imaging in [68 Ga]Ga-PSMA-11 PET/CT","authors":"A. Aghaee , Z. Bakhshi , V. Roshanravan , N. Norouzbeigi , H. Dadgar , E. Askari , K. Aryana , S. Shafiei , S. Soltani , S. Sadeghpour","doi":"10.1016/j.remnie.2025.500184","DOIUrl":"10.1016/j.remnie.2025.500184","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aims to evaluate the diagnostic value of early static and delayed imaging in conjunction with standard 68Ga-PSMA-11 PET/CT scans to detect prostate malignant lesions in prostate cancer patients.</div></div><div><h3>Methods</h3><div>One hundred and thirty-eight prostate cancer patients underwent routine [68 Ga]Ga-PSMA-11 PET/CT imaging, 4-minute static acquisition post-injection, and delayed imaging 3 h post-injection. The imaging results were analysed for lesion count, type, localisation, and maximum standardised uptake values.</div></div><div><h3>Results</h3><div><span>57.97% exhibited positive findings for pathologic prostatic lesions in the standard PET scans (SUV</span><sub>max</sub>: 10.24). In contrast, early PET imaging detected lesions in 58.01% of patients (SUV<sub>max</sub><span> of 5.86), while delayed scans revealed lesions suggestive of malignancy in 55.45% of patients (SUV</span><sub>max</sub> of 12.79). The analysis demonstrated a statistically significant difference in SUV<sub>max</sub> values across the time points (<em>P</em><span><span> < .001). Pathologic lymph nodes on images 60 min p.i. were revealed by an SUV max 60 min p.i.: 15.78; this number for the first 4 min and after 3 h were 7.36, 19.19, respectively. Metastatic bone lesions<span> on WB were found in 38 patients, more than the ESI (n = 37) and DI (n = 24). In comparison, urinary bladder activity assessment was detectable with the </span></span>WB imaging SUV</span><sub>max</sub><span> 60 min 11.07. Even though the SUV max for ESI and DI were 6.95 and 31.97, respectively. In the statistical analysis, pathologic radiotracer uptake in tumour lesions was statistically higher in ESI and WB than in urinary bladder activity.</span></div></div><div><h3>Conclusions</h3><div>The findings indicate that neither early [68 Ga]Ga-PSMA-11 PET/CT nor delayed imaging significantly enhanced the overall detection rate of malignant lesions in prostate cancer patients. However, the early 4-minute post-injection acquisition of PET images proved beneficial for distinguishing local bladder invasion more effectively.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 1","pages":"Article 500184"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidental detection of bone metastases from gastric cancer on [99mTc]Tc-DTPA renal dynamic scintigraphy [99mTc]Tc-DTPA肾动态显像偶然发现胃癌骨转移。

Revista espanola de medicina nuclear e imagen molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remnie.2025.500196

C. Nong, Y. Xing, L. Jiang, Z. Zhao

引用次数: 0

Treatment with [166Ho]Ho-labeled polylactic acid microspheres in a patient with giant focal nodular hyperplasia [166Ho] ho标记聚乳酸微球治疗巨大局灶性结节增生1例。

Revista espanola de medicina nuclear e imagen molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remnie.2025.500204

J.J. Martin-Marcuartu , J.L. Vercher-Conejero , B. Hervás-Sanz , J. Valcarcel José , L. Llado Garriga , M. Cortes-Romera

引用次数: 0

Impact of perinodal infiltration on recurrence in papillary thyroid cancer 淋巴结周围浸润对甲状腺乳头状癌复发的影响。

Revista espanola de medicina nuclear e imagen molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remnie.2025.500182

A. Cinar , U.M. Turan , K. Okuyucu , N. Aydinbelge Dizdar , A. Erol , B. Bedi Alpay , P. Akkus Gunduz , M. Ozkara , D. Cayir , E. Alagoz , S. Ince

Introduction and objectives

Locoregional recurrence occurs in up to 28% of patients with papillary thyroid cancer (PTC). Several risk factors contribute to this metastatic process. The latest of them is perinodal infiltration (PNI). PNI refers to the pathological extension of tumor cells through the lymph node (LN) capsule into the perinodal fibroadipose tissue. It has been accepted as a poor predictive variable. This study aimed to evaluate the prognostic significance of PNI in recurrence of PTC and identify predictive parameters associated with the recurrence in PNI (+) patients.

Material and methods

The study included 680 PTC patients with initial LN metastasis (ILNM). Study population was selected from them according to presence or absence of PNI. Eventually, 102 PNI (+) and 122 PNI (−) patients remained eligible for the study. Patients were statistically compared according to demographic, clinicopathologic features both between PNI (+) and PNI (−) groups and within the PNI (+) group over recurrence status.

Results

The recurrence rates were 40% and 15% in PNI (+) and PNI (−) patients, respectively (p < 0.001). The independent predictive factors associated with recurrence were central ILNM (p = 0.005), combined central and lateral ILNM (p = 0.003), ILNM > 5 (p = 0.023), stage III–IV (p = 0.025 and p < 0.001), tumor size (TS) (p < 0.001), ILNM size (p < 0.001), stimulated thyroglobulin (sTg) (p = 0.039). PNI (p = 0.05), central ILNM (p = 0.035) and TS (p = 0.027) remained prognostic variables after multivariate analysis.

Conclusion

PNI positivity is a poor prognostic factor for PTC recurrence. PNI, especially with large TS and central ILNM, should be taken into account when planning RAI therapy in PTC patients.

简介和目的：局部复发发生在高达28%的患者乳头状甲状腺癌（PTC）。几个危险因素有助于这种转移过程。其中最新的是周淋巴结浸润（PNI）。PNI是指肿瘤细胞通过淋巴结（LN）囊进入结周纤维脂肪组织的病理性扩展。它被认为是一个很差的预测变量。本研究旨在评估PNI在PTC复发中的预后意义，并确定与PNI（+）患者复发相关的预测参数。材料与方法：本研究纳入680例原发性淋巴结转移（ILNM）的PTC患者。根据是否存在PNI从他们中选择研究人群。最终，102名PNI（+）和122名PNI（-）患者仍符合研究条件。根据人口学、临床病理特征对PNI（+）组与PNI（-）组之间以及PNI（+）组内患者的复发情况进行统计学比较。结果：PNI（+）和PNI（-）患者复发率分别为40%和15% (p = 0.023)， III-IV期（p = 0.025）和p。结论：PNI阳性是PTC复发的不良预后因素。PNI，特别是大TS和中枢性ILNM，在规划PTC患者的RAI治疗时应考虑到。

{"title":"Impact of perinodal infiltration on recurrence in papillary thyroid cancer","authors":"A. Cinar , U.M. Turan , K. Okuyucu , N. Aydinbelge Dizdar , A. Erol , B. Bedi Alpay , P. Akkus Gunduz , M. Ozkara , D. Cayir , E. Alagoz , S. Ince","doi":"10.1016/j.remnie.2025.500182","DOIUrl":"10.1016/j.remnie.2025.500182","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Locoregional recurrence occurs in up to 28% of patients with papillary thyroid cancer (PTC). Several risk factors contribute to this metastatic process. The latest of them is perinodal infiltration (PNI). PNI refers to the pathological extension of tumor cells through the lymph node (LN) capsule into the perinodal fibroadipose tissue. It has been accepted as a poor predictive variable. This study aimed to evaluate the prognostic significance of PNI in recurrence of PTC and identify predictive parameters associated with the recurrence in PNI (+) patients.</div></div><div><h3>Material and methods</h3><div><span>The study included 680 PTC patients with initial LN metastasis (ILNM). Study population was selected from them according to presence or </span>absence of PNI. Eventually, 102 PNI (+) and 122 PNI (−) patients remained eligible for the study. Patients were statistically compared according to demographic, clinicopathologic features both between PNI (+) and PNI (−) groups and within the PNI (+) group over recurrence status.</div></div><div><h3>Results</h3><div><span><span>The recurrence rates were 40% and 15% in PNI (+) and PNI (−) patients, respectively (p < 0.001). The independent predictive factors associated with recurrence were central </span>ILNM<span> (p = 0.005), combined central and lateral ILNM (p = 0.003), ILNM > 5 (p = 0.023), stage III–IV (p = 0.025 and p < 0.001), tumor size (TS) (p < 0.001), ILNM size (p < 0.001), stimulated thyroglobulin (sTg) (p = 0.039). PNI (p = 0.05), central ILNM (p = 0.035) and TS (p = 0.027) remained prognostic variables after </span></span>multivariate analysis.</div></div><div><h3>Conclusion</h3><div><span>PNI positivity is a poor prognostic factor for </span>PTC recurrence. PNI, especially with large TS and central ILNM, should be taken into account when planning RAI therapy in PTC patients.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"45 1","pages":"Article 500182"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Revista espanola de medicina nuclear e imagen molecular

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀